Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and Outlook
Izotropic (OTCQB: IZOZF) released a CEO interview outlining near-term execution for its flagship IzoView dedicated breast CT platform.
Planned use of proceeds over the next 12–18 months includes funding for 3 IzoView devices, capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE‑mark activities, and two additional CE‑focused devices to build data and accelerate regulatory pathways. The CEO highlighted an exclusive CADx patent for breast CT and potential recurring revenues beyond device sales, and discussed regulatory, clinical, and market risks into 2026 with mitigation strategies.
Izotropic (OTCQB: IZOZF) ha rilasciato un'intervista al CEO che descrive l'esecuzione a breve termine per la sua piattaforma CT al seno di punta IzoView.
I piani di utilizzo dei proventi nei prossimi 12–18 mesi includono il finanziamento di 3 dispositivi IzoView, capitale per un prossimo studio clinico della U.S. FDA, un dispositivo partner nel Regno Unito mentre si avviano le attività di CE‑mark, e due ulteriori dispositivi focalizzati su CE per costruire dati e accelerare i percorsi normativi. Il CEO ha evidenziato una patente CADx esclusiva per la mammografia CT e potenziali ricavi ricorrenti oltre la vendita dei dispositivi, e ha discusso rischi regolatori, clinici e di mercato fino al 2026 con strategie di mitigazione.
Izotropic (OTCQB: IZOZF) lanzó una entrevista con el CEO que describe la ejecución a corto plazo para su plataforma de CT mamario de referencia IzoView.
El uso previsto de los ingresos durante los próximos 12–18 meses incluye financiamiento para 3 dispositivos IzoView, capital para un próximo estudio clínico de la FDA estadounidense, un dispositivo asociado en el Reino Unido mientras se inician las actividades de CE‑mark, y dos dispositivos adicionales centrados en CE para generar datos y acelerar las vías regulatorias. El CEO destacó una patente exclusiva de CADx para la mamografía CT y posibles ingresos recurrentes más allá de la venta de dispositivos, y analizó riesgos regulatorios, clínicos y de mercado hasta 2026 con estrategias de mitigación.
Izotropic (OTCQB: IZOZF)은 대표적인 가슴 CT 플랫폼 IzoView에 대한 단기 실행 계획을 설명하는 CEO 인터뷰를 발표했습니다.
향후 12–18개월 동안의 예정 프로ceeds 사용에는 3개의 IzoView 장치에 대한 자금 조달, 미국 FDA 임상 연구를 위한 자본, CE‑mark 활동을 시작하는 동안 영국에서의 파트너 장치 하나, 그리고 데이터 구축과 규제 경로를 가속하기 위한 두 개의 추가 CE 중심 장치가 포함됩니다. CEO는 유방 CT를 위한 독점 CADx 특허와 장치 판매를 넘어선 잠재적 반복 수익, 그리고 규제, 임상 및 시장 위험을 2026년까지 논의하며 완화 전략을 제시했습니다.
Izotropic (OTCQB: IZOZF) a publié une interview du PDG décrivant l'exécution à court terme pour sa plateforme CT mammaire IzoView phare.
L'utilisation prévue des produits sur les 12–18 prochains mois comprend le financement de 3 dispositifs IzoView, des capitaux pour une prochaine étude clinique de la FDA américaine, un appareil partenaire au Royaume-Uni tout en lançant les activités CE‑mark, et deux dispositifs supplémentaires axés CE pour constituer des données et accélérer les voies réglementaires. Le PDG a souligné un brevet exclusif CADx pour la CT mammaire et des revenus récurrents potentiels au-delà de la vente des dispositifs, et a discuté des risques réglementaires, cliniques et de marché jusqu'en 2026 avec des stratégies d'atténuation.
Izotropic (OTCQB: IZOZF) veröffentlichte ein CEO-Interview, in dem die kurzfristige Umsetzung für die flaggschiffnahe IzoView Dedicated Breast-CT-Plattform dargelegt wird.
Geplante Verwendung der Erlöse in den nächsten 12–18 Monaten umfasst die Finanzierung von 3 IzoView-Geräten, Kapital für eine kommende klinische Studie der U.S. FDA, ein Partnergerät im Vereinigten Königreich, während CE‑Mark-Aktivitäten eingeleitet werden, sowie zwei zusätzliche CE-fokussierte Geräte zum Aufbau von Daten und zur Beschleunigung regulatorischer Wege. Der CEO hob eine exklusive CADx‑Patent für Brust-CT hervor und potenzielle wiederkehrende Einnahmen jenseits des Geräteverkaufs, und diskutierte regulatorische, klinische und Marktrisiken bis 2026 mit Abmilderungsstrategien.
Izotropic (OTCQB: IZOZF) أصدرت مقابلة مع الرئيس التنفيذي تستعرض التنفيذ على المدى القريب لمنصة CT الثدي IzoView الرائدة.
يشمل استخدام العائدات المخطط خلال 12–18 شهراً القادم تمويل 3 أجهزة IzoView، ورأس مال لدراسة إكلينيكية أمريكية FDA، وجهاز شريك في المملكة المتحدة أثناء بدء أنشطة CE‑mark، وجهازين إضافيين موجهين لـ CE لبناء البيانات وتسريع مسارات التنظيم. أشار الرئيس التنفيذي إلى براءة اختراع CADx حصرية لـ CT الثدي وإيرادات محتملة متكررة بخلاف مبيعات الأجهزة، ونوقشت المخاطر التنظيمية والسريرية والسوقية حتى 2026 مع استراتيجيات التخفيف.
Izotropic (OTCQB: IZOZF) 发布了CEO访谈，概述其旗舰 IzoView 专用乳腺CT平台的近期执行计划。
在接下来的 12–18 个月 内，计划的资金用途包括为 3台 IzoView 设备提供资金、为即将进行的美国 FDA 临床研究筹集资本、在英国进行合作设备并启动 CE‑mark 活动，以及另外两台以 CE 为重点的设备以创建数据并加速监管路径。CEO 强调了用于乳腺CT 的独家 CADx 专利及设备销售之外的潜在经常性收入，并讨论到 2026 年的监管、临床和市场风险及其缓解策略。
- Planned funding for 3 IzoView devices over 12–18 months
- Capital allocated for a forthcoming U.S. FDA clinical study
- One partner device planned in the U.K. alongside CE‑mark activities
- Exclusive CADx patent for breast CT supporting differentiation
- Regulatory and clinical risks extend into 2026
- Time‑to‑market depends on successful CE‑mark and FDA study outcomes
- Execution reliant on raising sufficient proceeds for planned device deployments
Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of a new video interview with the Company's CEO in partnership with Departures Capital.
The interview delves into the Company's story and near-term execution plan around its flagship device, IzoView, a dedicated breast CT platform. In the discussion, CEO Bob Thast shares the founding vision and leadership context, then unpacks IzoView's features while explaining the science, patient implications, and how it differentiates in the breast-imaging market. He outlines planned use of proceeds over the next 12-18 months, including three devices and capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE-mark activities, and two additional devices for markets that accept the CE-mark-focused on building data to accelerate regulatory pathways and time-to-market. Thast also discusses Izotropic's exclusive CADx patent for breast CT, and future recurring revenues beyond device sales, while candidly addressing key regulatory, clinical, and market risks into 2026 and mitigation strategies. Watch the full interview here to learn more: https://www.youtube.com/watch?v=LFeUW7J2jYU.
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR+ at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271531
FAQ
What near‑term plans did Izotropic (IZOZF) outline for IzoView in the CEO interview?
When does Izotropic expect to use proceeds and deploy IzoView devices (IZOZF)?
Does Izotropic (IZOZF) have intellectual property protecting IzoView?
Will Izotropic conduct a U.S. FDA clinical study for IzoView (IZOZF)?
How will CE‑mark activities affect Izotropic's (IZOZF) commercialization plan?
What are the key investor risks mentioned for Izotropic (IZOZF)?
